It isn’t just artificial intelligence. Chinese biotech companies are now developing drugs faster and cheaper than their US ...

Merck desperately needs Moderna's mRNA-based ... therapy could be the lifeline Merck desperately needs. Founded in Cambridge, Massachusetts in 2010, Moderna was an early pioneer in the development ...

The Cambridge, Massachusetts-based biotech's personalized cancer vaccine mRNA-4157, developed with Merck (MRK), is currently in late-stage development targeting patients with skin cancer melanoma.

Goldman's downgrade comes days after the Cambridge, Massachusetts-based biotech slashed ... personalized cancer vaccine mRNA-4157 developed with Merck (MRK), the analyst cited potential revenue ...

The company's newer product, an RSV ( respiratory syncytial virus) vaccine, has also underperformed, contributing "minimal sales" in 2024. Analysts' concerns were heightened by the company's revised ...

Kennedy "made millions off of lawsuits against the same vaccine makers he’d regulate as health secretary," Warren said.

Kim, an associate professor of biology at the Massachusetts Institute of Technology in Cambridge who also holds appointments ... On July 12, Kim, 36, will receive the DuPont Merck Young Investigator ...

GSK said it is paying $2.1 billion upfront for Cambridge, Massachusetts-based Affinivax ... That rise came despite the approval of Merck & Co's 15-valent Vaxneuvance in July 2021, which has ...

Why Merck (MRK) Stock Is Falling Today What Happened? Shares of global pharmaceutical company Merck (NYSE:MRK) fell 11% in the morning session after the company reported mixed fourth-quarter earnings.